See clearly. Treat optimally.
Image of See clearly. Treat optimally international campaign
See clearly. Treat optimally.

Proven solutions for optimal patient outcomes.

Optimal patient outcomes start with the power of IVUS. Only Philips offers the powerful combination of advanced imaging and specialized treatment options designed to accurately assess inside the vessel, successfully select the right treatment algorithm, and optimize outcomes for your patients.

The intersection of imaging and therapy

Our clinically proven peripheral vascular portfolio provides advanced imaging and specialized treatment options so you can effectively and efficiently maximize patient outcomes.
Identifies plaque burden location for precise treatment
Guides device sizing to allow drug delivery
Provides insights on plaque type to guide device selection
Confirms true lumen or sub-intimal guidewire location

IVUS real-world results to improve patient outcomes [9,10]

  1. 83%

    primary patency [11]

    83%

    primary patency [11]

    A recently published RCT comparing IVUS guided vs Angiography guided angioplasty for the outcomes of DCB in the treatment of Femoropopliteal artery disease demonstrated statistically significant better primary patency when IVUS was used (83.8% v 70.1%, p=0.01)

  2. 92.4%

    freedom from CD-TLR [11]

    92.4%

    freedom from CD-TLR [11]

    A recently published RCT comparing IVUS guided vs Angiography guided angioplasty for the outcomes of DCB in the treatment of Femoropopliteal artery disease demonstrated statistically significant better freedom from CD-TLR when IVUS was used (92.4 v 83.0%, p=0.03)

  3. 89.1%

    sustained clinical improvement [11]

    89.1%

    sustained clinical improvement [11]

    A recently published RCT comparing IVUS guided vs Angiography guided angioplasty for the outcomes of DCB in the treatment of Femoropopliteal artery disease demonstrated statistically significant better sustained clinical improvement when IVUS was used (89.1 v 76.3%, p=0.02)

  4. 57%

    IVUS changed 57% of venous treatment plans [12]

    57%

    IVUS changed 57% of venous treatment plans [12]

    In VIDIO, in 35 patients IVUS changed plan from no treatment to stent placement; in 13 patients it changed number of stents planned; in 6 patients it changed plan from no treatment to other intervention; in 3 patients it changed plan from treatment to no treatment [12].

The intersection of imaging and therapy

Our clinically proven peripheral vascular portfolio provides advanced imaging and specialized treatment options so you can effectively and efficiently maximize patient outcomes.

Plug-and-play IVUS platform available

Exceptional mobile or integrated platform built for smart, simple and seamless lab integration, ready for tomorrow’s innovations.

Complete portfolio of IVUS catheters:

A full line of IVUS catheters to help guide your treatment strategies.

Phoenix Mechanical Atherectomy System.

The safe, simple and effective choice [1-7]: It is simple and has a cut, capture and clear mechanism with no need for capital equipment for ATK &BTK.

The innovative, safe [8] and versatile solution

Philips Laser System: Vaporizes complex morphologies with one technology. It photoablates tissues to become smaller than a red blood cell [x].

Phoenix Mechanical Atherectomy System. The safe, simple and effective choice.
Phoenix treats a broad range of tissue types, from soft plaque to calcified arteries, and can be used for lesions above and below the knee.*,** Phoenix presents proven clinical evidence in over 1,000 patients resulting in <1% symptomatic distal embolization with no filter used [1-7]. Learn more
Image of Phoenix Mechanical Atherectomy System
AngioSculpt Scoring Balloon Catheter. Scoring means results.
Rectangular scoring edges lock the device in place and are designed to drive outward expansion with up to ~15–25 times the force of a conventional balloon [13]. AngioSculpt has low dissection rates and minimal perforations [14,15].
Image of OR during a peripheral interventions
Quick-Cross Support Catheter. The support you need to handle complex lesions
Hydrophilic coating and low profile tapered tip for crossing challenging lesions: Straight or angled shaft configurations, multiple wire compatibilities and up to four working lengths tailored to your needs, three evenly spaced radiopaque markers to facilitate catheter positioning.
Image of OR peripheral vascular interventions.
Laser Atherectomy. Innovative. Safe. Versatile.
Laser atherectomy is versatile as it vaporizes complex morphologies with one technology. It captures the power of ultraviolet light to provide a reliable tool for treating multiple lesion morphologies within PAD lesions. It is the only laser atherectomy device with level 1 clinical data [8].
Laser Atherectomy Innovative Safe Versatile

Anytime I go inside a blood vessel, I use intravascular ultrasound… the quality of my intervention goes up significantly.

Bryan T. Fisher, Sr., MD
Vascular Surgeon 
HCA Healthcare
Doctors in operating room
Footnotes
  1. Davis T, Ramaiah V, Niazi K, Martin Gissler H, Crabtree T. Safety and effectiveness of the Phoenix atherectomy system in lower extremity arteries: Early and midterm outcomes from the prospective multicenter EASE study. Vascular. 2017 Dec;25(6):563-575
  2. Gandini R, A Single-Center Experience With Phoenix Atherectomy System in Patients With Moderate to ©2021 Heavily Calcified Femoropopliteal Lesions, Cardiovascular Revascularization Medicine 21 (2020), 676–681
  3. Giusca S, Safety, effectiveness and mid-term follow-up in 136 consecutive patients with moderate to severely calcified lesions undergoing phoenix atherectomy, Heart and Vessels, Oct 2020
  4. Janas A, Comparison of long-term outcomes after directional versus rotational atherectomy in peripheral artery disease, Adv Interv Cardiol 2020; 16, 1 (59): 76–81
  5. Giusca S, Hagstotz S, Lichtenberg M, Heinrich U, Eisenbach C, Andrassy M, Korosoglou G. Phoenix atherectomy for patients with peripheral artery disease. EuroIntervention. 2022 Aug 5;18(5):e432-e442. doi: 10.4244/EIJ-D-21-01070. PMID: 35389346.
  6. Shishehbor et al. Acute Real-World Outcomes From the Phoenix Post-Approval Registry. J Invasive Cardiol. 2022 Jan;34(1):E1-E7. Epub 2021 Dec 19/
  7. Kumarasamy A, Gombert A, Krabbe J, Ruprecht O, Jacobs MJ, Krabbe H. Assessment of Feasibility and Patency of below the Knee Atherectomy Using the 1.5 mm Phoenix Catheter-A Retrospective Study. Medicina (Kaunas). 2022 Nov 3;58(11):1594. doi: 10.3390/medicina58111594. PMID: 36363551; PMCID: PMC9699591.
  8. Dippel EJ, et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovasc Interv. 2015 Jan;8(1 Pt A):92-101. doi: 10.1016/j.jcin.2014.09.009. Epub 2014 Dec 10. PMID: 25499305.
  9. Divakaran S, Meissner MH, Kohi MP, et al. Utilization of and Outcomes Associated with Intravascular Ultrasound during Deep Venous Stent Placement among Medicare Beneficiaries. J Vasc Interv Radiol. 2022;33(12):1476-1484.e2. doi:10.1016/j.jvir.2022.08.018]
  10. Divakaran S, Parikh SA, Hawkins BM, et al. Temporal Trends, Practice Variation, and Associated Outcomes With IVUS Use During Peripheral Arterial Intervention. JACC Cardiovasc Interv. 2022;15(20):2080-2090. doi:10.1016/j.jcin.2022.07.050
  11. Allan R, Puckridge P, Spark J, et al. The Impact of Intravascular Ultrasound on Femoropopliteal Artery Endovascular Interventions. J Am Coll Cardiol Intv. 2022 Mar, 15 (5) 536–546. https://doi.org/10.1016/j.jcin.2022.01.001
  12. Gagne PG, TaharaRW, FastabendCP,etal. Venography versus intravascular ultrasound for diagnosing and treating iliofemoral vein obstruction. J VascSurg:Venousand LymDis 2017;5:678-87.
  13. AngioSculpt Test Plan ST-1197 (2008), on file at Philips.
  14. Kiesz RS, Scheinert D, Peeters PJ, et al. Results from the international registry of the AngioSculpt Scoring Balloon Catheter for the treatment of infrapoplitealdisease. J Am Coll Cardiol. 2008;51:10 (suppl B);75.
  15. Scheinert D, Peeters P, Bosiers M, et al. Results of the multicenter first-in-man study of a novel scoring balloon catheter for the treatment of infra-popliteal peripheral arterial disease. Catheter Cardiovasc Interv. 2007;70:1034-1039.
Disclaimer
Always read the label and follow the directions for use. Philips medical devices should only be used by physicians and teams trained in interventional techniques, including training in the use of this device. Products subject to country availability. Please contact your local sales representative. ©2025 Koniklijke Philips N.V. All rights reserved. Trademarks are the property of Koninklijke Philips N.V. or their respective owners. Philips reserves the right to change product specifications without prior notification.
* Monitor flow of excised material into the disposal reservoir during operation of the Catheter. If flow of excised material ceases during the procedure, this is a sign that the Catheter drive system (cutter, torque shaft, or Handle motor drive) may not be operating properly.
** The Phoenix atherectomy 1.5 mm tracking catheter is indicated for vessels of 2.0 mm in diameter or above, the 1.8 mm tracking catheter is indicated for vessels 2.5 mm in diameter or above. The Phoenix 2.2 mm tracking and deflected as well as the 2.4 mm deflecting catheters are indicated for vessels of 3.0 mm in diameter or above. While the 1.5mm and 1.8 tracking as well as the 2.2 mm tracking and deflecting catheters are indicated for femoral, popliteal, or distal arteries located below the knee, the Phoenix 2.4 mm deflecting catheter is indicated for femoral and popliteal only. Refer to product IFU for detailed instructions.
[X] Mechanism and Implementation of Catheter-Based Ultraviolet Photoablation, Christopher Reiser, Ph.D
See clearly. Treat optimally.